Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$7.38 USD
+0.04 (0.54%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $7.32 -0.06 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
KYTX 7.38 +0.04(0.54%)
Will KYTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYTX
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)
Kyverna Therapeutics price target lowered by $1 at H.C. Wainwright, here's why
Buy Rating Affirmed for Kyverna Therapeutics Amid Strong Clinical Safety Profile and FDA Momentum
Wall Street Analysts Are Bullish on Top NA Picks